<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203371</url>
  </required_header>
  <id_info>
    <org_study_id>APS 001/2010</org_study_id>
    <secondary_id>BRA10APS001</secondary_id>
    <nct_id>NCT01203371</nct_id>
  </id_info>
  <brief_title>Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS</brief_title>
  <official_title>PHASE III, DOUBLE-BLIND, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF NAFTOPIDIL AND TAMSULOSIN TO TREATMENT THE SYMPTOMS OF LOWER URINARY TRACT IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apsen Farmaceutica S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apsen Farmaceutica S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of Naftopidil and
      Tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of
      patients with benign prostatic hyperplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:

      Men ≥ 50 years Signs and symptoms of BPH A total IPSS of ≥ 10 Prostate volume of ≥20 mL
      (estimated by ultrasonography) PVR &gt; 150mL
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Prostate Symptom Score</measure>
    <time_frame>2, 4, 8 and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect</measure>
    <time_frame>2, 4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Naftopidil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0,25 mg (2 weeks) and 0,50 mg (10 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsusolin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,4 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftopidil</intervention_name>
    <description>0,25 mg (2weeks) and 0,50 mg (10 weeks)</description>
    <arm_group_label>Naftopidil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>0,4 mg/day</description>
    <arm_group_label>Tamsusolin</arm_group_label>
    <other_name>SECOTEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men ≥ 50 years

          -  Signs and symptoms of BPH

          -  IPSS of ≥ 10

          -  Prostate volume of ≥ 20 mL

          -  PVR &gt; 150 mL

        Exclusion Criteria:

          -  History of allergy to a AR antagonists

          -  Treatment with antiandrogen drugs

          -  Drugs with anticholinergic activity

          -  Significant history of orthostatic hypotension

          -  Concomitant neurological diseases

          -  Known or suspected neurogenic bladder dysfunction

          -  Carcinoma of the prostate or bladder

          -  Previous surgery for BPH or bladder neck obstruction

          -  History of recurrent UTI

          -  Concomitant active UTI
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabiane F Machado</last_name>
    <phone>55 11 5644 8211</phone>
    <email>fabiane.machado@apsen.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristiane P Lima</last_name>
    <phone>55 11 5644 8200</phone>
    <phone_ext>8269</phone_ext>
    <email>cristiane.lima@apsen.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina da USP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geraldo C Freire, PhD</last_name>
      <phone>55 11 3069-8082</phone>
    </contact>
    <contact_backup>
      <last_name>Camila C Marin</last_name>
      <phone>55 11 3069-8082</phone>
      <email>camila.marin@ig.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Geraldo C Freire, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>September 15, 2010</last_update_submitted>
  <last_update_submitted_qc>September 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Apsen Farmacêutica S.A.</name_title>
    <organization>Apsen</organization>
  </responsible_party>
  <keyword>naftopidil</keyword>
  <keyword>symptoms of lower urinary tract</keyword>
  <keyword>benign prostate hyperplasia</keyword>
  <keyword>LUTS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Naftopidil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

